Stealth BioTherapeutics enrols first subject in dry AMD treatment trial
A new dry AMD study. The rate of change in the macular area of photoreceptor loss is the primary efficacy endpoint of ReNEW and ReTAIN trials. Stealth BioTherapeutics has enrolled…